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Background and purpose   Corticosteroid treatment is associated 
with osteonecrosis of the femoral head (ON) in certain patients. 
The degree of drug sensitivity in general is governed by genetic 
variation between individuals. We investigated the relationship 
between ON and the presence of different alleles of the cytochrome 
P450 gene (CYP3A4), the product of which metabolizes corticoste-
roids, and of the P-glycoprotein (P-gp) gene (ABCB1), the product 
of which modulates cellular uptake of corticosteroids, to deter-
mine whether patients with certain alleles may be at higher risk 
of ON after corticosteroid treatment. 
Methods   We studied 31 patients from Guangdong, China who 
were both treated with corticosteroid therapy and developed ON, 
and 17 corticosteroid-therapy patients without ON. Patient DNA 
was  screened  for  known  polymorphisms  in  the  CYP3A4  gene 
(CYP3A4*4, CYP3A4*5, CYP3A4*6) and the P-gp gene ABCB1 
(mutations C3435T, G2677T/A). 
Results      The  majority  (20/31)  of  the  corticosteroid-treated 
patients  who  developed  ON  were  heterozygous  for  ABCB1, 
whereas only 3/17 without ON were heterozygous. Statistical sig-
nificance was observed between the ON and the control groups for 
the ABCB1 G2677T/A polymorphism. Analysis of haplotypic fre-
quencies indicated significant linkage disequilibrium between the 
two ABCB1 polymorphisms, C3435T and G2677T/A (D' = 0.034). 
No CYP3A4 polymorphisms were detected in any of the patients.
Interpretation   Patients carrying an ABCB1 polymorphism had 
a higher risk of having corticosteroid-associated ON than those 
with wild-type genotypes. This statistically significant association 
conflicts with previous studies, possibly due to different sampling 
methods. Knowing which genetic backgrounds are most strongly 
associated with corticosteroid-associated ON provides a method 
of screening for patients who are most at risk of developing ON.  

Non-traumatic osteonecrosis (ON) of the femoral head is the 
gradual destruction of the femur head due to loss of blood flow 
and osteocyte death; it is characterized by disruption of intra-
vascular blood flow, cellular toxicity, and impaired differentia-
tion of mesenchymal cells, ultimately leading to bone death 
(Lieberman et al. 2003). Both arterial circulation—compro-
mised by femoral neck fracture or arterial thrombosis/apop-
tosis  from  systemic  diseases  (e.g.  lupus  erythematous  and 
hemoglobinopathies) (Mankin 1992)—and high intraosseous 
pressure, resulting from prolonged corticosteroid administra-
tion or ethanol abuse, obstruct blood flow in the femoral head 
and increase marrow cellularity and fat (Drescher et al. 2006). 
Although discreet pathogenetic mechanisms have yet to be 
identified in ON, corticosteroid and ethanol abuse have a pro-
found effect on physiological bone turnover and oxygenation, 
and are associated with more than 90% of all osteonecrosis 
cases (Schroer 1994). The varying frequency and the clinical 
course of ON development in patients taking large doses of 
corticosteroids have been increasingly attributed (in part) to 
the presence of single nucleotide polymorphisms (SNPs) in 
the DNA sequences of genes encoding metabolic enzymes 
such as P-glycoprotein (P-gp) and cytochrome P450 (Asano 
et al. 2003b). 
P-gp  is  an  ATP-dependent  membrane  efflux  pump  that 
maintains  intracellular  drug  and  xenobiotic  concentrations 
below cytotoxic levels (Tsuji et al. 1997). P-gp is encoded 
by the multidrug-resistance 1 (MDR1) gene, also known as 
the ABC transporter B1 (ABCB1) gene (Sakaeda et al. 2002). 
Corticosteroids are well established to be a P-gp substrate 
(Saeki et al. 1993). Numerous SNPs in the ABCB1 gene have 
been identified, two of which (C3435T and G2677T/A) have 
been widely studied and associated with functional changes 
in P-gp expression or activity (Tanabe et al. 2001). Interin-
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expression and the pharmacokinetics of corticosteroids and 
metabolites, contributing to the cortisol sensitivity of certain 
individuals and increasing the risk of developing ON. A prog-
nostic relationship between the ABCB1 C3435T and G2677T/
A  polymorphisms  and  cortisol-associated  ON  development 
has recently been established (Tanabe et al. 2001, Asano et 
al. 2003a).
The cytochrome P450 family is a group of enzymes involved 
in the oxidative and reductive metabolism of almost all lipid-
soluble medicines. The product of the cytochrome P450 gene, 
CYP3A4, is considered to be the main cytochrome respon-
sible for steroid metabolism (Kitada et al. 1987). CYP3A4 
also exhibits an approximate 40-fold degree of interindividual 
polymorphic variation, including CYP3A*1-*5 alleles, which 
have  been  associated  with  reduced  activity  of  cytochrome 
P450  (Hsieh et al. 2001), a prognostic factor associated with 
increased incidence of ON and with the extent of necrotic 
infiltration in a rabbit model (Masada et al. 2008).
The objective of the present study was to assess the inci-
dence  of  ABCB1  C3435T  and  G2677T/A  genotypes,  and 
of  polymorphisms  of  CYP3A4  (CYP3A4*4,  CYP3A4*5, 
CYP3A4*6) in a multicenter, randomized post-corticosteroid 
therapy patient cohort with or without corticosteroid-associ-
ated ON. Clarification of the prevalence of specific genetic 
polymorphisms in corticosteroid-associated ON patients will 
encourage greater acknowledgement of the prophylactic mea-




The study protocol was approved by the local institutional and 
administrative review board of the First Affiliated Hospital of 
Guangzhou TCM University, and all patients provided writ-
ten informed consent before participation. All were from the 
Guangdong Province of China. 31 consecutive randomized 
patients who were treated with corticosteroid therapy and had 
documented ON, and 17 consecutive corticosteroid-therapy 
patients without ON were included in this study. The patients 
were diagnosed with ON in accordance with the criteria pre-
scribed by Sugano et al. (2002). Patient history of corticoste-
roid use, exposure to hyperbaric conditions, known systemic 
and other concomitant diseases, and hemoglobinopathies were 
obtained by review of patient charts. Corticosteroid-associated 
ON patients were defined as those who took continuous corti-
costeroid medication for at least 2 months before physical and 
radiological examination of the hips. Patients with ON prior to 
corticosteroid administration or those with a history of ethanol 
abuse were excluded.
Sequence analysis of the CYP3A4*4, CYP3A4*5, and 
CYP3A4*6 polymorphisms and the ABCB1 C3435T 
and G2677T/A polymorphisms 
CYP3A4*4, CYP3A4*5, and CYP3A4*6 polymorphisms and 
ABCB1 C3435T and G2677T/A polymorphisms were deter-
mined by sequencing polymerase chain reaction (PCR) prod-
ucts of the polymorphic regions from each patient, as previ-
ously described (Asano et al. 2003a). Briefly, genomic DNA 
for PCR was extracted from peripheral blood samples using 
the DNeasy Tissue Kit (Qiagen Gmbh, Hilden, Germany) fol-
lowing the manufacturer’s instructions. Oligonucleotide prim-
ers for PCR amplification were derived from known sequences 
(GenBank  accession  number  M29445  for  C3435T  and 
M29440 for G2677T/A). The sequences for the CYP primers 
were: forward 5’-CAC ATT TTC TAC AAC CAT GGA GAC 
C-3’ and reverse 5’-TTT TAT ACC TGT CCC CAC CAG 
ATT C-3’ for CYP3A4*4; forward 5’-TGT TGC ATG CAT 
AGA GGA AGG ATG G-3' and reverse 5’-GAT GAC AGG 
GTT TGT GAC AGG GG-3’ for CYP3A4*5; and forward 5’-
GAG CCA TAT TCT CAG AAG GGA GAT CAA G-3' and 
reverse 5’-CAA ACA TGT GTC GTT CTG CTA TGT GG-3’ 
for CYP3A4*6. The sequences for the ABCB1 primers were: 
forward 5'-TTC AGC TGC TTG ATG GCA AA-3' and reverse 
5'-AGG CAG TGA CTC GAT GAA GG-3' for C3435T; and 
forward 5'-CAG GCT TGC TGT AAT TAC CC-3' and reverse 
5'-TAG TTT GAC TCA CCT TCC CA-3' for G2677T/A. The 
PCR amplification program consisted of an initial denaturation 
step at 94°C for 5 min, followed by 35 cycles of denaturation 
at 94°C for 1 min, annealing at 58°C for 1 min and extension 
at 72°C for 1 min, and a final extension at 72°C for 5 min. The 
resulting PCR fragments were then purified and sequenced 
using BigDye Terminator sequencing reactions in an auto-
mated DNA sequencer (ABI 3730; Applied Biosystems).
Statistics
Post-randomization  clinical  data  and  patient  characteristics 
were stratified in terms of post-cortisol-associated ON patients 
and post-cortisol patients without ON. Statistical analysis of 
polymorphisms in the ABCB1 gene was conducted using the 
chi-square test or Fisher’s exact test. Haplotype frequencies 
were estimated using pairwise linkage disequilibrium coef-
ficients calculated from estimated haplotype frequencies of 




The distribution of sex and age between the ON group (31 
patients) and the control group (17 patients) was similar, with 
14 females and 17 males with a median age of 32 (12–58) 
years in the ON group, and 9 females and 8 males with a 
median age of 30 (19–59) years in the control group. Patients Acta Orthopaedica 2009; 80 (3): 325–329  327
were admitted for a variety of conditions requiring corticoste-
roid therapy. In the ON group, the patients were admitted for 
trauma (4), psoriasis (2), rubeola (2), renal disease (5), mixed 
connective tissue disease (3), systemic lupus erythematosus 
(7), atopy (2), rheumatoid arthritis (1), renal transplantation 
(1), asthma (1), mycotic opthalmia (1), aplastic anaemia (1), 
or chronic pharyngitis (1). In the control group, patients were 
admitted for renal disease (10) or systemic lupus erythemato-
sus (7).
Incidence of ABCB1 C3435T and G2677T/A polymor-
phisms 
Of the 31 ON patients who were genotyped for the ABCB1 
C3435T polymorphism, 24 had the wild-type CC genotype, 7 
had the heterozygous CT phenotype, and none had the homo-
zygous TT phenotype. Of the 17 control patients, 14 had CC, 
3 had CT, and none had TT.
Of the 31 ON patients who were genotyped for the ABCB1 
G2677T/A polymorphism, 18 had the wild-type GG genotype, 
9 had the heterozygous GT phenotype, 4 had the heterozygous 
GA phenotype, and none had any of the remaining possible 
polymorphic phenotypes. Of the 17 control patients, all 17 had 
the wild-type GG phenotype.
In the ON group, 20/31 patients carried one copy of a poly-
morphic allele of either C3435T (n = 7) or G2677T/A (n = 13), 
and 13 of all 31 patients carrying ABCB1 polymorphic alleles 
developed corticosteroid-associated ON. 24 patients homo-
zygous for the wild-type 3435CC sequence and 18 patients 
homozygous for the 2677GG polymorphism developed ON 
subsequent to corticosteroid administration.
There was significant difference between the ON and con-
trol group for SNPs in the ABCB1 G2677T/A polymorphism 
(p = 0.002, Table 1). Analysis of haplotypic frequencies by 
Fisher’s  exact  test  indicated  significant  linkage  disequilib-
rium between C3435T and G2677T/A (D' = 0.03), which is in 
agreement with the results of Asano et al. (2003a) (Table 2).
Incidence of CYP3A4*4, CYP3A4*5, and CYP3A4*6 
polymorphisms
Using  sequence  analysis,  no  CYP3A4*4,  CYP3A4*5,  or 
CYP3A4*6  polymorphisms  were  detected.  These  findings 
were discordant in part with the previously published results 
of Asano et al. (2003b).
Discussion
Our results indicate a statistically significant difference between 
the ON and control groups regarding the ABCB1 C3435T and 
G2677T/A SNPs, suggesting a positive association between 
these genetic polymorphisms and the susceptibility of corti-
costeroid-associated ON. It is interesting that this result con-
flicts with the observation of Asano et al. (2003a), in which the 
C3435T (3435TT genotype, but not 3435CT genotype) and 
G2677T/A (2677TT, 2677TA, and 2677AA genotypes) SNPs 
were associated with a reduced risk of corticosteroid-associ-
ated ON. Ethnic background should probably be considered 
to be the primary cause of this diversity. To date, 28 SNPs in 
the ABCB1 gene have been reported at 27 positions in Cauca-
sians and Africans (Hoffmeyer et al. 2000, Kim et al. 2001, 
Siegmund et al. 2002), of which only a few C3435T SNPs 
were associated with P-gp expression, function, or increased 
plasma concentration. Other studies have also found a diversi-
fied allelic frequency in the wobble SNP in C3435T, with Cau-
casians and Japanese showing frequencies different from those 
of Africans (Saeki et al. 1993). The involvement of the 3435T 
variant allele has been reported previously by Siegmund et al. 
(2002), in which healthy Japanese patients harboring the allele 
had lower serum concentrations of digoxin after a single injec-
tion as compared to wild-type subjects. Other studies have 
shown conflicting results, with a lack of genotype-phenotype 
correlation between C3435T SNPs and cyclosporine efficacy 
in renal transplantation patients, indicating that C3435T is not 
the only polymorphism involved in P-gp expression (Sakaeda 
et al. 2001). However, recent studies have shown that carri-
ers of the ABCB1 3435T allele have enhanced oral clearance 
of cyclosporine compared to Caucasian individuals with the 
3435CC  genotype  (von Ahsen  et  al.  2001),  and  they  have 
reduced expression of intestinal CYP3A4 mRNA (Yates et al. 
2003). 
A  statistically  significant  linkage  disequilibrium  between 
the  C3435T  and  G2677T/A  SNPs  was  identified  in  both 
this study and that of Asano et al. (2003a), corroborating the 
involvement of the ABCB1 C3435T and G2677T/A SNPs in 
the pathogenesis of corticosteroid-associated ON. However, 
whether the involvement is a risk factor for or against corti-
Table 1. Single nucleotide polymorphisms (SNPs) of ABCB1 exon 
26 (C3435T) and exon 21 (G2677T/A) (n = 48)
  SNP C3435T  SNP G2677T/A
SNPs  ON   Control  p-value a   ON  Control  p-value a
No   24   14    18   17  
Yes   7   3   1.0   13   0  0.002
a Fisher’s exact test.
Table 2. Chi-squared test of independence for single nucleotide 
polymorphisms (SNPs) of ABCB1: C3435T and G2677T/A (n = 48)
  G2677T/A
C3435T  SNPs
SNPs   No   Yes   p-value a  D' b
No   15   9   0.4   0.03
Yes   3   4 
Total   18   13  
a Fisher’s exact test.
b Linkage disequilibrium coefficient (D')328  Acta Orthopaedica 2009; 80 (3): 325–329
costeroid-associated ON remains to be determined. Although 
the physiological role of P-gp remains elusive, interindividual 
expression of the highly polymorphic ABCB1 gene is likely 
to contribute to variability in the pharmacokinetics and phar-
macodynamics of many drugs (Saeki et al. 1993) in addition 
to increased susceptibility to cancer (Siegsmund et al. 2002). 
C3435T and G2677T/A SNPs do not involve amino acid sub-
stitution and do not functionally influence P-gp expression 
directly (Siegmund et al. 2002). Thus, their functional sig-
nificance may be that they are involved in post-transcriptional 
mRNA processing and affect the quality or quantity of P-gp 
protein expression.
The frequencies of the C3435T alleles in our test groups 
were much different from those reported for normal healthy 
Han Chinese populations (reviewed in Li et al. 2006). Previous 
studies of Han Chinese populations from Singapore, southwest 
China, and Northern China showed a typical Hardy-Weinberg 
distribution of genotypes. In contrast, our data show a low fre-
quency of T alleles. It is likely that our results may have been 
affected by both sampling error due to low sample size and 
by the fact that the samples came from unhealthy individuals. 
Similar conclusions may be drawn regarding the G2677T/A 
allele, based on its strong linkage to the C3435T allele.
The  CYP3A  subfamily  of  cytochrome  P450  proteins  are 
found most abundantly in the liver and intestine, accounting 
for approximately 95% of the CYP3A mRNA-pool in Cauca-
sians (Koch et al. 2002). The protein products of CYP3A4 and 
CYP3A5 are preferentially involved in the catalysis of exog-
enous and endogenous compounds. Contrary to the expected 
SNP variability of CYP3A genes (Hsieh et al. 2001), all of the 
subjects in our patient cohort were homozygous wild-types. 
Certain alleles of these genes (CYP3A4*4 and CYP3A4*5) 
are associated with clinically relevant changes in drug clear-
ance (Felix et al. 1998, Thervet et al. 2003). Our study design 
did not allow for measurement of the systemic clearance of 
CYP3A  substrate  drugs  in  relation  to  development  of  ON; 
however, recent studies have shown that the CYP alleles we 
examined are rare in the Chinese population (Hsieh et al. 2001, 
Wen et al. 2004). Instead, the Chinese population contains a 
number of novel CYP mutations that are rare in other popula-
tions (Du et al. 2006). We suggest evaluation of the roles of 
other CYP3A genes in relation to ON and control groups, with 
clearly identifying the substrate regiments of the gene prod-
ucts in the future. 
Interestingly, all the patients who did not develop ON had 
either kidney disease or lupus. Both kidney disease (Naud et 
al. 2008) and lupus (Tsujimura et al. 2005) can increase P-
gp activity. It is possible that these diseases counteracted any 
genetic influences on corticosteroid clearance by upregulating 
P-gp expression, thus providing protection against ON.
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